Sugi Predict

Sugi Predict / Compounds / SCHEMBL1401788

SCHEMBL1401788

SCHEMBL1401788

C#CCN1CCN(C[C@@H](O)COc2cc3ncnc(Oc4ccc5[nH]c(C)cc5c4F)c3cc2OC)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.62
▸ EGFR P00533 4/20 0.62
▸ RET P07949 3/20 0.62
▸ PDGFRB P09619 3/20 0.62
▸ FGFR1 P11362 3/20 0.62
▸ EPHB6 O15197 2/20 0.62
▸ RIPK2 O43353 2/20 0.62
▸ STK10 O94804 2/20 0.62
▸ MAP4K4 O95819 2/20 0.62
▸ ABL1 P00519 2/20 0.62
▸ LCK P06239 2/20 0.62
▸ CSF1R P07333 2/20 0.62
▸ HCK P08631 2/20 0.62
▸ KIT P10721 2/20 0.62
▸ SRC P12931 2/20 0.62
▸ PDGFRA P16234 2/20 0.62
▸ FLT1 P17948 2/20 0.62
▸ FGFR2 P21802 2/20 0.62
▸ FGFR4 P22455 2/20 0.62
▸ FGFR3 P22607 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401789 1.00 KDR (0.62) KDREGFRRETPDGFRBFGFR1
SCHEMBL3193747 0.91 KDR (0.74) KDREGFRRETPDGFRBFGFR1
SCHEMBL3193752 0.91 KDR (0.74) KDREGFRRETPDGFRBFGFR1
SCHEMBL1401716 0.88 KDR (0.62) KDREGFRRETPDGFRBFGFR1
SCHEMBL1401718 0.88 KDR (0.62) KDREGFRRETPDGFRBFGFR1
SCHEMBL1401685 0.87 KDR (0.82) KDREGFRRETPDGFRBFGFR1
SCHEMBL1401645 0.86 KDR (0.65) KDREGFRRETPDGFRBFGFR1
SCHEMBL1401644 0.86 KDR (0.65) KDREGFRRETPDGFRBFGFR1
SCHEMBL4662561 0.82 KDR (0.44) KDREGFRRETPDGFRBFGFR1
SCHEMBL4373823 0.80 KDR (0.68) KDREGFRRETPDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US claimed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP claimed
US-20080027069-A1 Quinazoline compounds ASTRAZENECA AB 2008-01-31 — — US claimed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US claimed
EP-1474420-A1 QUINAZOLINE COMPOUNDS Astrazeneca AB (SE) 2004-11-10 — — EP claimed
WO-2003064413-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-08-07 — — WO claimed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP disclosed
US-20100029673-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE ASTRAZENECA AB (SE) 2010-02-04 — — US disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 — — US disclosed
US-7268230-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2007-09-11 — — US disclosed
US-20060223815-A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use ASTRAZENECA AB (SE) 2006-10-05 — — US disclosed
EP-1620104-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE Astrazeneca AB (SE) 2006-02-01 — — EP disclosed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US disclosed
WO-2004098604-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE ASTRAZENECA AB (SE) 2004-11-18 — — WO disclosed
EP-1474420-A1 QUINAZOLINE COMPOUNDS Astrazeneca AB (SE) 2004-11-10 — — EP disclosed
WO-2003064413-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223815-A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use SRC, TEK, FLT4 KDR 5/4885EGFR 124/4885RET 145/4885
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents VEGFA, FLT4, FLT1 KDR 4/4885EGFR 1095/4885RET 3578/4885
US-20100029673-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE SRC, CHUK, CTTN KDR 10/4885EGFR 233/4885RET 209/4885
US-20090156821-A1 Quinazoline compounds VEGFA, FLT4, FLT1 KDR 5/4885EGFR 1610/4885RET 2725/4885
US-20080027069-A1 Quinazoline compounds VEGFA, FLT4, FLT1 KDR 5/4885EGFR 1610/4885RET 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.